CTLA4 and acute myeloblastic leukemia with maturation: Despite lower levels of TILs and a reduced frequency of PD-L1 expression, recent advancements in immunotherapy have shown that anti-PD-1 and anti-CTLA-4 combination therapies are beneficial for patients with AM and are now considered the standard of care [82,83,84].